Canaccord Genuity Maintains Buy on Insulet, Raises Price Target to $234
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Kyle Rose maintains a Buy rating on Insulet (NASDAQ:PODD) and raises the price target from $226 to $234.
May 10, 2024 | 6:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity's analyst Kyle Rose reaffirmed a Buy rating on Insulet and increased the price target from $226 to $234, indicating a positive outlook on the company's stock.
The increase in price target by a reputable analyst suggests a strong confidence in Insulet's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100